Onco Actu du 12 juillet 2016

	1. Biologie
International collaboration to create new cancer models to accelerate research [National Cancer Institute] “As part of NCI’s Precision Medicine Initiative in Oncology, this new project is timed perfectly to take advantage of the latest cell culture and genomic sequencing techniques to create models that are representative of patient tumors and are annotated with genomic and clinical information. This effort is a first step toward learning how to use these tools to design individualized treatments.”
Global initiative seeks 1,000 new cancer models [Nature News & Comment] The initiative’s models will offer several improvements over most available cell lines. Each line will be matched with clinical data about the donor patient, and how they responded to treatment.
	3.1.1 Tabac - e-cigs
E-cigarettes are used by teens who wouldn’t otherwise smoke, study finds [STAT] The finding echoes the results of a paper published by the same group of researchers in May that found that teenagers who give e-cigarettes a try are much more likely to try regular cigarettes within a year than their peers who haven’t vaped.
E-cigarettes contribute to increased tobacco use by teens [Reuters] The researchers wondered whether e-cigarettes are recruiting youth who otherwise would never have smoked. The answer seems to be yes, said Dr. Jessica L. Barrington-Trimis from University of Southern California, Los Angeles.
	4.2 Dép., diag. & prono. - Génome
Advancing precision diagnostics in oncology: VHIO to co-develop novel Next-Next Generation Sequencing [Vall d'Hebron Institute Oncology] Pharmaceutical company Roche selects the Vall d´Hebron Hospital Campus Barcelona as the first ever test-center for novel mass-sequencing platform.
	4.9 Dép., diag. & prono. - Sein
Myriad Announces Positive Results for an EndoPredict® Clinical Study Published in the Journal of the National Cancer Institute [Myriad] EPclin (EndoPredict) Markedly Outperformed RS (Oncotype DX®) Across the 10-Year Follow-up Period" in a Large Head-to-Head Breast Cancer Study.
	5.12 Immunothérapies
Biomarkers for Immunotherapy: Results from ASCO 2016 [The OBR Blog] The current oncology model of using a single biomarker to select patients for treatment may not be the best approach in the era of immunotherapy.
	5.2 Pharma
AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414 for the Treatment of a Type of Pediatric Brain Tumor known as Diffuse Intrinsic Pontine Glioma [AbbVie] In 2014, the FDA and European Medicines Agency granted ABT-414 Orphan Drug Designation for the treatment of glioblastoma and glioma in adults, respectively
CytRx Sarcoma Drug Flops Late-Stage Clinical Trial [The Street] The aldoxorubicin sarcoma study failure leaves CytRx with a depleted pipeline and 40 cents per share in cash.
CytRx Announces Initial Results of Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft [PR Newswire] For the current evaluation, the study did not show a significant difference between aldoxorubicin and investigator's choice therapy for PFS, with a median of 4.17 months and 4.04 months, respectively, for the study's primary endpoint.
	5.2.1 Pharma - Partenariats
Sorrento nabs PD-1 deal with Servier [FierceBiotech] Wall Street was underwhelmed by the Servier announcement, pulling Sorrento down a further 3% in early trading on the news--putting its share price down by roughly one-quarter so far this year.
	5.2.3 Pharma - économie
Price Gouging and the Dangerous New Breed of Pharma Companies [Harvard Business Review] The main reason the new kind of pharma companies has taken an interest in this market is that the Orphan Drug Act (ODA) substantially increases the potential profits.
	5.4 Traitements - Economie
A Fair Plan For Fairer Drug Prices [Health Affairs] In the absence of reforms to make drug pricing more competitive, the political alternative may well be regulated pricing. This approach would end up skewing investment because it would inevitably allocate capital based on political priorities rather than scientific priorities and clinical goals.
	6.10 Politiques
UK scientists dropped from EU projects because of post-Brexit funding fears [The Guardian] Doubts over the UK’s ability to win future project grants mean some EU partners are avoiding working with British researchers.
	6.10.1 Politiques (USA)
Obama blames high drug prices on companies too worried about profits [STAT] “We need to continue to tackle special interest dollars in politics. But we also need to reinforce the sense of mission in health care that brought us an affordable polio vaccine and widely available penicillin.”
Senate delays Cures bill, as window for major legislation narrows [STAT] The legislation is supported by the pharmaceutical and medical device industries as well as patient advocacy groups, but public watchdog groups worry that it would undermine the Food and Drug Administration’s efforts to make sure the new products are safe.
Next President Should Attack Drug Prices, Obama Says in JAMA [Bloomberg] The article includes 68 citations and endnotes, though it was not formally peer-reviewed and JAMA published it as a "special communication."
	6.4 Médico-éco
A chain of for-profit cancer centers has been advertising more than all its competitors combined [STAT] The Cancer Treatment Centers of America spent $101.7 million promoting its services in TV, print, online, and other ads in 2014, accounting for nearly 60 percent of all ad spending by US cancer centers that year, according to a new study from researchers at Indiana University and the University of Pittsburgh.
Cancer hospital advertising triples since 2005 [Reuters] “There is a concern among some physicians that such advertising may persuade patients to pursue high-cost treatments with a low likelihood of improving outcomes.”
	6.7.2 Applis
Dana-Farber, Fitbit partner for breast cancer study [FierceHealthcare] The Dana-Farber Cancer Institute is relying on fitness trackers for a massive breast cancer study on whether exercise can reduce cancer recurrence. The devices used for the study are being provided by Fitbit, free of charge.